In the REALM study, the most frequent mutations were observed in TP53 and KRAS like in two others F1CDx retrospective cohort studies [19, 20], respectively Japanese in a pan-tumor population, and Finnish in lung cancer only (between 2004 and 2017). This evidence concerns the gene KRAS and lung cancer.